REVB

SEC source: 0001193125-26-355663 · ownership.xml · nonDerivative · entry 1

Rolke James · CIK 0001693858 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 422,814

F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

SEC source: 0001193125-26-355662 · ownership.xml · nonDerivative · entry 1

Chawla Lakhmir S · CIK 0001646626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,169

F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

SEC source: 0001193125-26-355661 · ownership.xml · nonDerivative · entry 3

Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 300,136

F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

F2 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

SEC source: 0001193125-26-355661 · ownership.xml · nonDerivative · entry 2

Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

SEC source: 0001193125-26-355661 · ownership.xml · nonDerivative · entry 1

Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 208,073

F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

SEC source: 0001193125-26-355659 · ownership.xml · nonDerivative · entry 1

ROPER JESS · CIK 0001408993 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,839

F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

SEC source: 0001193125-26-355658 · ownership.xml · nonDerivative · entry 1

CARVER JENNIFER · CIK 0001663163 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,769

F1 · shares: These shares are subject to a restricted stock award granted under the Revelation Biosciences, Inc. 2021 Equity Incentive Plan, with 50% of the shares vesting on the two-year anniversary of the grant date, and the remaining 50% of the shares vesting on the four-year anniversary of the grant date, provided that the Reporting Person remains continuously employed by or provides services to the Company or any subsidiary through the applicable vesting date; and provided, further that such vesting could be accelerated upon the achievement of certain performance milestones.

SEC source: 0001193125-26-201769 · ownership.xml · nonDerivative · entry 1

Rolke James · CIK 0001693858 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 214,738

F1 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.12 to $1.14, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001193125-26-201764 · ownership.xml · nonDerivative · entry 1

Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · by Trust

Disclosed balance after: 92,063

F1 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.09 to $1.13, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F3 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

SEC source: 0001193125-26-039686 · ownership.xml · nonDerivative · entry 1

Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 105,348

F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.63 to $1.66, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

F4 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

SEC source: 0001193125-26-039695 · ownership.xml · nonDerivative · entry 1

Chawla Lakhmir S · CIK 0001646626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,158

F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

SEC source: 0001193125-26-039700 · ownership.xml · nonDerivative · entry 1

ROPER JESS · CIK 0001408993 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,828

F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.84 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

SEC source: 0001193125-26-039693 · ownership.xml · nonDerivative · entry 1

CARVER JENNIFER · CIK 0001663163 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,758

F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.87 to $1.88, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

SEC source: 0001193125-26-039690 · ownership.xml · nonDerivative · entry 1

Rolke James · CIK 0001693858 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 224,853

F1 · shares: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

F2 · shares: Represents shares sold by the issuer on behalf of the reporting person solely to satisfy required tax withholding obligations arising upon the vesting of restricted stock awards. The transaction was mandatory and the reporting person did not exercise investment discretion with respect to the sale.

F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 to $1.87, inclusive. The reporting person undertakes to provide to Revelation Biosciences, Inc. (REVB), any security holder of REVB, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

F1 · balance_after: All share numbers reflect a 1-for-4 reverse stock split effective January 28, 2026.

SEC source: 0001193125-26-010648 · ownership.xml · nonDerivative · entry 2

Rolke James · CIK 0001693858 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 933,489

F1 · security: Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant.

SEC source: 0001193125-26-010642 · ownership.xml · nonDerivative · entry 3

Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 473,790

F1 · security: Restricted Stock Units under the 2021 Equity Incentive Plan. Vests quarterly over two years from the date of grant.

F2 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

SEC source: 0001193125-26-010625 · ownership.xml · nonDerivative · entry 2

CARVER JENNIFER · CIK 0001663163 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,669

F1 · security: Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

SEC source: 0001193125-26-010613 · ownership.xml · nonDerivative · entry 2

ROPER JESS · CIK 0001408993 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,667

F1 · security: Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

SEC source: 0001193125-26-010586 · ownership.xml · nonDerivative · entry 2

Chawla Lakhmir S · CIK 0001646626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 57,667

F1 · security: Restricted Stock Unit under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

SEC source: 0001193125-25-260426 · ownership.xml · nonDerivative · entry 2

Chawla Lakhmir S · CIK 0001646626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,686

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026.

SEC source: 0001193125-25-260423 · ownership.xml · nonDerivative · entry 2

Rolke James · CIK 0001693858 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 400,660

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the grant date.

SEC source: 0001193125-25-260419 · ownership.xml · nonDerivative · entry 2

CARVER JENNIFER · CIK 0001663163 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,688

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026.

SEC source: 0001193125-25-260417 · ownership.xml · nonDerivative · entry 3

Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 395,645

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests quarterly over one year from the date of grant.

F2 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

SEC source: 0001193125-25-260415 · ownership.xml · nonDerivative · entry 2

ROPER JESS · CIK 0001408993 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,686

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on January 28, 2026

SEC source: 0000950170-25-020126 · ownership.xml · nonDerivative · entry 1

Chawla Lakhmir S · CIK 0001646626 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 181

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

SEC source: 0000950170-25-020120 · ownership.xml · nonDerivative · entry 2

CARVER JENNIFER · CIK 0001663163 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 187

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

SEC source: 0000950170-25-020113 · ownership.xml · nonDerivative · entry 2

ROPER JESS · CIK 0001408993 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 183

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

SEC source: 0000950170-25-020109 · ownership.xml · nonDerivative · entry 2

Rolke James · CIK 0001693858 · Director · Chief Executive Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,137

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

SEC source: 0000950170-25-020104 · ownership.xml · nonDerivative · entry 3

Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 15,076

F1 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

F2 · ownership.nature: Shares are held by The Zygmont Family Trust Dated October 25, 2016, with respect to which Chester S Zygmont III is a trustee.

SEC source: 0000950170-25-020097 · ownership.xml · nonDerivative · entry 2

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 268

F2 · security: Restricted Stock Grant under the 2021 Equity Incentive Plan. Vests 100% on date of grant.

F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust

SEC source: 0001209191-23-058296 · doc4.xml · nonDerivative · entry 1

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

SEC source: 0001209191-23-052953 · doc4.xml · nonDerivative · entry 1

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 42,096

F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

SEC source: 0001209191-23-053102 · doc4.xml · nonDerivative · entry 1

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 27,771

SEC source: 0001209191-23-051037 · doc4.xml · nonDerivative · entry 1

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Indirect · By Trust

Disclosed balance after: 42,096

F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

SEC source: 0001209191-23-049786 · doc4.xml · nonDerivative · entry 3

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,348

SEC source: 0001209191-23-049786 · doc4.xml · nonDerivative · entry 2

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 43,348

SEC source: 0001209191-23-049786 · doc4.xml · nonDerivative · entry 1

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,848

SEC source: 0001209191-23-024898 · doc4.xml · nonDerivative · entry 2

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 64,848

SEC source: 0001209191-23-024898 · doc4.xml · nonDerivative · entry 1

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 39,848

F1 · price: Represents the weighted-average price at which shares were purchased within a range between $1.14 and $1.17. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001209191-23-024646 · doc4.xml · derivative · entry 1

TIDMARSH GEORGE F · CIK 0001287235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,356

Underlying: Common Stock · 6,356 shares

Expires 2033-04-14

F1 · derivative.exercise_date: The stock options vest and become exercisable on the grant date.

SEC source: 0001209191-23-024643 · doc4.xml · derivative · entry 1

ROPER JESS · CIK 0001408993 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,356

Underlying: Common Stock · 6,356 shares

Expires 2033-04-14

F1 · derivative.exercise_date: The stock options vest and become exercisable on the grant date.

SEC source: 0001209191-23-024638 · doc4.xml · derivative · entry 1

LaBelle Curt H · CIK 0001396235 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,356

Underlying: Common Stock · 6,356 shares

Expires 2033-04-14

F1 · derivative.exercise_date: The stock options vest and become exercisable on the grant date.

SEC source: 0001209191-23-024634 · doc4.xml · derivative · entry 1

CARVER JENNIFER · CIK 0001663163 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 6,356

Underlying: Common Stock · 6,356 shares

Expires 2033-04-14

F1 · derivative.exercise_date: The stock options vest and become exercisable on the grant date.

SEC source: 0001209191-23-013633 · doc4.xml · derivative · entry 1

Zygmont Chester Stanley III · CIK 0001900657 · Chief Financial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 611 shares

Expires 2032-02-25

F1 · derivative.exercise_date: The stock options were granted on 2/25/2022 and vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date.

SEC source: 0001209191-23-013629 · doc4.xml · derivative · entry 1

Rolke James · CIK 0001693858 · Director · Chief Executive Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 2,542 shares

Expires 2032-02-25

F1 · derivative.exercise_date: The stock options were granted on 2/25/2022 and vest 25% on the one-year anniversary of the grant date, and thereafter quarterly over a three-year period, subject to continued service through each such vesting date.

SEC source: 0001209191-22-013741 · doc4.xml · nonDerivative · entry 1

TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 467,156

SEC source: 0001209191-22-008580 · doc4.xml · nonDerivative · entry 2

TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 447,156

F1 · price: Represents the weighted-average price at which shares were purchased within a range between $2.53 and $2.57. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

SEC source: 0001209191-22-008580 · doc4.xml · nonDerivative · entry 1

TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 417,156

SEC source: 0001209191-22-007837 · doc4.xml · nonDerivative · entry 2

TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · Trust

Disclosed balance after: 1,523,335

F2 · price: Represents the weighted-average price at which shares were purchased within a range between $2.50 and $2.6817. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.

SEC source: 0001209191-22-008025 · doc4a.xml · nonDerivative · entry 2

TIDMARSH GEORGE F · CIK 0001287235 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · By Trust

Disclosed balance after: 1,523,335

F2 · price: Represents the weighted-average price at which shares were purchased within a range between $2.50 and $2.6817. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.

F1 · ownership.nature: Shares are held by George Tidmarsh, Trustee George Francis Tidmarsh 2021 Irrevocable Trust with respect to which George Tidmarsh is a trustee.